GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Total Equity

Gan & Lee Pharmaceuticals Co (SHSE:603087) Total Equity : ¥11,312 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co Total Equity?

Gan & Lee Pharmaceuticals Co's total equity for the quarter that ended in Mar. 2025 was ¥11,312 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Gan & Lee Pharmaceuticals Co Total Equity Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co Total Equity Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,938.36 10,167.14 9,585.64 10,742.51 11,054.47

Gan & Lee Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,842.59 10,977.09 11,206.86 11,054.47 11,312.12

Gan & Lee Pharmaceuticals Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Gan & Lee Pharmaceuticals Co's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=12042.916-988.446
=11,054

Gan & Lee Pharmaceuticals Co's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=12284.435-972.311
=11,312

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gan & Lee Pharmaceuticals Co Total Equity Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Gan & Lee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines